Braveheart Bio, Inc. (BRVE) · Nov 6, 2026 · Other events
At the bar — 79% below 30 mmHg at Week 52; 90% reached the threshold at least once
Braveheart Bio’s new HCM trial data show durable obstruction relief, preserved systolic function and a broader case for treating non-obstructive disease.
Braveheart is a newly public, single-asset biotech trying to move BHB-1893 from encouraging HCM Phase 2 data into global late-stage development, with its global obstructive-HCM Phase 3 program already initiated and a non-obstructive-HCM Phase 3 planned. The market already knew the direction: prior Phase 2 results were positive, an interim extension snapshot had shown a high response rate, and the AHA presentations were scheduled in advance.
The filing supports durability, but does not rewrite the story. After a year of treatment, 79% of patients were below the clinically important 30 mmHg gradient threshold, while 90% reached it at least once; exercise capacity and quality-of-life scores also improved. 〔0〕 The result is clinically encouraging and broadly clears the proof-of-concept bar for moving toward a fixed-dose Phase 2b study, but it is an open-label, 42-patient extension rather than controlled evidence.
| Measure | Week 52 | Baseline / comparator | Other comparison |
|---|---|---|---|
| pVO2 change (OLE) (Exercise capacity) | +2.7 mL/kg/min | OLE baseline | 70% reached ≥1.5 |
| KCCQ-CSS change (OLE) (Quality of life) | +17.3 points | OLE baseline | 45% reached ≥20 |
| Valsalva LVOT-G <30 mmHg (oHCM) | 79% (33/42) | — | 90% at any visit |
| Maintained at 40 mg BID | 57% (24/42) | — | 19% at 60 mg BID |
| Septal e' above 7 cm/s (nHCM) | 59% | 20% baseline | 14% control |
| Transient LVEF below 50% | 2 patients | — | 48% and 49% |
The strongest incremental signal is simplicity and breadth. More than half of patients finished on the 40 mg twice-daily starting dose, and no on-treatment severe or serious adverse events or permanent discontinuations were reported. 〔1〕 That supports Braveheart’s effort to differentiate the drug through less complicated titration and monitoring, although two transient LVEF reductions show that cardiac-function monitoring is not eliminated. 〔2〕
The non-obstructive data widen the commercial and biological claim, but remain exploratory. Improvements in diastolic-function measures, preserved systolic performance and supporting engineered-heart-tissue findings suggest BHB-1893 may address more than obstruction. 〔3〕 However, these are post hoc analyses from a completed Phase 2 study, so they strengthen the rationale for the next trial more than they establish disease modification.
Bottom line: This is a credible, mildly positive confirmation of BHB-1893’s durability, tolerability and dosing simplicity, with a useful expansion into diastolic dysfunction. It advances the existing Phase 3 story rather than fundamentally changing it.
TRUEHEART-HCM Phase 2b initiation
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!